Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CERUS CORPCERS · Entity 5431 | Director | June 06, 2017 | June 13, 2017 |
| Jazz Pharmaceuticals plcJAZZ · Entity 818 | Director | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CERUS CORP
Report date June 06, 2017 · Filed June 13, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,921 |
Reported balance
After 2017-06-06 transaction · row 1
1 source rowRow 1 · 2017-06-06 · Exercise / conversion · Acquired 10,133 · Balance 18,921 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-06 · Exercise / conversion · Disposed 10,133 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 15,853 |
Reported balance
After 2017-06-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-06-07 · Grant · Acquired 15,853 · Balance 15,853 F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3: Not applicable. F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. |
| Option Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $2.61 · Expires 2027-06-06 | Direct | 38,005 |
Reported balance
After 2017-06-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-06-07 · Grant · Acquired 38,005 · Balance 38,005 F3: Not applicable. F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock.
F2: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders.
F3: Not applicable.
F4: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.
F5: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders.
Jazz Pharmaceuticals plc
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 345,875 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 6,000 · Balance 345,875 F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was made pursuant to a plan adopted by the reporting person on November 26, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. The transaction occurred automatically and does not represent a discretionary transaction by the reporting person.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ACELYRIN, Inc.
Report date May 21, 2025 · Filed May 23, 2025
Section 16 reporting ended · disclosed 2025-05-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.04 · Expires 2032-03-07 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-21 · Disposition to issuer · Disposed 183,434 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2033-05-03 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-05-21 · Disposition to issuer · Disposed 23,243 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 · Expires 2034-06-06 | Direct | 0 |
Reported balance
After 2025-05-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-05-21 · Disposition to issuer · Disposed 92,158 · Balance 0 F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent. F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48 of the shares subject to the option vested on April 7, 2022, and 1/48 of the shares subject to the option vests in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F2: On February 6, 2025, ACELYRIN, Inc., a Delaware corporation (the "Company"), entered into an Agreement and Plan of Merger (as amended on April 20, 2025, the "Merger Agreement") with Alumis, Inc., a Delaware corporation ("Parent"), and Arrow Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, on May 21, 2025, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving as a wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $0.00001 per share, of the Company issued and outstanding was converted into the right to receive 0.4814 (the "Exchange Ratio") shares of voting common stock of Parent, par value $0.0001 per share ("Parent Common Stock"), and cash in lieu of any fractional shares.
F3: Pursuant to the Merger Agreement, at the Effective Time each stock option that was outstanding and unexercised immediately prior to the Effective Time with a per share exercise price of $18.00 or less was assumed by Parent and converted into an option to purchase a number of shares of Parent Common Stock equal to (i) the number of shares subject to the option immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with any fractional shares rounded down to the nearest whole share, which stock option shall have an exercise price equal to (i) the per share exercise price for shares subject to the corresponding Company stock option immediately prior to the Effective Time, divided by (ii) the Exchange Ratio, rounded up to the nearest whole cent.
F4: 1/36 of the shares subject to the option vested on June 4, 2023, and 1/36 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
F5: All of the shares subject to the option vest on the earlier of (i) June 7, 2025, or (ii) the day immediately preceding the next annual meeting of stockholders following the grant date of the option, subject to the Reporting Person's continued service as a director through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2018 Filed Sep 25, 2018 22:02 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,300 | $164.36 | $213,668.00 |
DisclosureSEC source: 0001232524-18-000174 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 281,215 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 22:21 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,600 | $173.90 | $278,240.00 |
DisclosureSEC source: 0001232524-18-000126 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,515 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| July 02, 2018 Filed Jul 5, 2018 20:33 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,600 | $170.81 | $273,296.00 |
DisclosureSEC source: 0001232524-18-000117 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,115 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 22:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 4,000 | $168.01 | $672,040.00 |
DisclosureSEC source: 0001232524-18-000107 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,715 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 01, 2018 Filed Jun 5, 2018 22:50 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,000 | $170.00 | $510,000.00 |
DisclosureSEC source: 0001232524-18-000107 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,715 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 173 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2018. Read SEC document |
| May 01, 2018 Filed May 3, 2018 20:57 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $151.57 | $151,570.00 |
DisclosureSEC source: 0001232524-18-000085 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 292,542 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 21:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $150.01 | $150,010.00 |
DisclosureSEC source: 0001232524-18-000074 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,542 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $150.00 | $150,000.00 |
DisclosureSEC source: 0001232524-18-000068 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,542 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 21:12 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 4,288 | $143.39 | $614,856.32 |
DisclosureSEC source: 0001232524-18-000066 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,542 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 91,790 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000042 · edgardoc.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,790 Underlying: Ordinary Shares · 91,790 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 710 | $0.00 Strike: $140.67 | $0.00 |
DisclosureSEC source: 0001232524-18-000042 · edgardoc.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 710 Underlying: Ordinary Shares · 710 shares Expires 2028-02-29 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:27 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 37,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-18-000042 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,830 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2018, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 28, 2018 Filed Feb 28, 2018 22:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $150.00 | $150,000.00 |
DisclosureSEC source: 0001232524-18-000025 · edgardoc.xml · nonDerivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,830 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 22:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 3,638 | $143.80 | $523,144.40 |
DisclosureSEC source: 0001232524-18-000025 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,830 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 22:24 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 6,269 | $147.44 | $924,301.36 |
DisclosureSEC source: 0001232524-18-000025 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,468 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| January 12, 2018 Filed Jan 17, 2018 21:53 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 3,000 | $150.00 | $450,000.00 |
DisclosureSEC source: 0001232524-18-000002 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,737 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 73 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2017. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 21:03 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $150.00 | $150,000.00 |
DisclosureSEC source: 0001232524-17-000166 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 276,664 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| September 12, 2017 Filed Sep 13, 2017 23:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $153.52 | $153,520.00 |
DisclosureSEC source: 0001232524-17-000160 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,664 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · balance_after: Includes 173 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2017. Read SEC document |
| June 07, 2017 Filed Jun 13, 2017 01:32 UTC | CERUS CORP CERS · Entity 5431 | GrantRestricted Stock Unit · Derivative | 15,853 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039323 · doc4.xml · derivative · entry 4 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,853 Underlying: Common Stock · 15,853 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F5 · derivative.exercise_date: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. F5 · derivative.expiration_date: The restricted stock unit shall vest on the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. Read SEC document |
| June 07, 2017 Filed Jun 13, 2017 01:32 UTC | CERUS CORP CERS · Entity 5431 | GrantOption Right to Buy · Derivative | 38,005 | Not disclosed Strike: $2.61 | Not disclosed |
DisclosureSEC source: 0001209191-17-039323 · doc4.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,005 Underlying: Common Stock · 38,005 shares Expires 2027-06-06 F3 · price: Not applicable. F4 · derivative.exercise_date: The option shall vest in twelve (12) equal monthly installments on each monthly anniversary of the transaction date with the final vesting date being the earlier of (a) one year from the date of grant, or (b) the day prior to the 2018 Annual Meeting of Stockholders. Read SEC document |
| June 06, 2017 Filed Jun 13, 2017 01:32 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionRestricted Stock Unit · Derivative | 10,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039323 · doc4.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. F3 · price: Not applicable. F2 · derivative.exercise_date: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders. F2 · derivative.expiration_date: This restricted stock unit vested on the day prior to the 2017 Annual Meeting of Stockholders. Read SEC document |
| June 06, 2017 Filed Jun 13, 2017 01:32 UTC | CERUS CORP CERS · Entity 5431 | Exercise / conversionCommon Stock | 10,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-039323 · doc4.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock. Read SEC document |
| May 11, 2017 Filed May 12, 2017 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 17,927 | $153.68 | $2,754,931.73 |
DisclosureSEC source: 0001232524-17-000113 · edgardoc.xml · nonDerivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,491 F2 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $153.5200 to $154.0400. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| May 11, 2017 Filed May 12, 2017 23:14 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 12,073 | $153.17 | $1,849,214.17 |
DisclosureSEC source: 0001232524-17-000113 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,418 F1 · price: Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $152.5200 to $153.5150. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Read SEC document |
| April 11, 2017 Filed Apr 13, 2017 23:26 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | SaleOrdinary Shares | 1,000 | $152.12 | $152,120.00 |
DisclosureSEC source: 0001232524-17-000084 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,491 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:35 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 5,000 | $132.81 | $664,050.00 |
DisclosureSEC source: 0001232524-17-000069 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 309,491 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 85,766 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000058 · edgardoc.xml · derivative · entry 3 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,766 Underlying: Ordinary Shares · 85,766 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantIncentive Stock Option (right to buy) · Derivative | 734 | $0.00 Strike: $136.18 | $0.00 |
DisclosureSEC source: 0001232524-17-000058 · edgardoc.xml · derivative · entry 2 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 734 Underlying: Ordinary Shares · 734 shares Expires 2027-03-01 F2 · derivative.exercise_date: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 2, 2017, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:49 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | GrantOrdinary Shares | 34,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001232524-17-000058 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 314,491 F1 · kind: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units vest in equal annual installments over four years measured from the vesting commencement date of March 5, 2017, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in equal annual installments over the subsequent three years. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 22:06 UTC | Jazz Pharmaceuticals plc JAZZ · Entity 818 | Tax withholdingOrdinary Shares | 10,272 | $136.97 | $1,406,955.84 |
DisclosureSEC source: 0001232524-17-000027 · edgardoc.xml · nonDerivative · entry 1 COZADD BRUCE C · CIK 0001193210 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,891 F1 · kind: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units. F2 · balance_after: Includes 50 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on November 30, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.